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Background: MicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expression
with remarkable stability in sera. Several miRs are oncogenic (oncomiRs) and are deregulated in the pathogenesis
of breast cancer and function to inhibit tumor suppressors. Routine blood monitoring of these circulating
tumor-derived products could be of significant benefit to the diagnosis and relapse detection of early-stage breast
cancer (EBC) patients.
Methods: Aim of this project was to determine expression of miR-155, miR-19a, miR-181b, miR-24, relative to let-7a
in sera of 63 patients with EBC and 21 healthy controls. Longitudinal multivariate data analysis was performed to
stochastically model the serum levels of each of the oncomiRs during disease phases: from diagnosis, after surgery,
and following chemo/radiotherapy. Moreover, this analysis was utilized to evaluate oncomiR levels in EBC patients
subgrouped using current clinical prognostic factors including HER2, Ki-67, and grade III.
Results: EBC patients significantly over-express the oncomiRs at the time of diagnosis. Following surgical resection
the serum levels of miR-155, miR-181b, and miR-24 significantly decreased (p = 1.89e-05, 5.41e-06, and 0.00638,
respectively) whereas the miR-19a decreased significantly after the therapy (p = 0.00869). Furthermore, in case
of high-risk patients serum levels of miR-155, miR-19a, miR-181b, and miR-24 are significantly more abundant
in comparison to low-risk group (p = 0.026, 0.02567, 0.0250, and 0.00990) and show a decreasing trend upon
therapy.
Conclusions: OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at
diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be
useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
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Left untreated, early-stage breast cancer (EBC) can pro-
gress into a deadly disseminated cancer and thus early
detection is of utmost importance. In addition to BRCA
mutations that occur within a relatively small patient co-
hort there exists other pathology risk factors such as
hormonal receptors, HER2, Ki-67, and grade III that aide* Correspondence: tstopka@lf1.cuni.cz
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unless otherwise stated.in determining the potential risk of disease progression
or relapse. MicroRNAs (miRs) are additional factors that
are related to tumor growth and are detectable in a pa-
tient specimen [1]. MicroRNAs are 18–24 nucleotide-
long non-coding RNAs each of them able to inhibit
hundreds of mRNAs. MicroRNAs are produced as genes
and function to inhibit their target mRNAs based on
complementarity, thus take part in normal cellular pro-
cesses as well as BC oncogenesis [2]. MicroRNAs are
exported outside the cells and due to their stability are
readily detectable in peripheral blood samples. ThisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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creted from the expanding EBC tissue.
Work by others involving 76 BC samples and 10 con-
trol tissues and utilizing microarray technique followed
by Northern blot validations demonstrated that miRs
are deregulated in BC with a defined ‘signature’ often
observed; decreased: miR-10b, miR-125b, miR-145, in-
creased: miR-21, and miR-155 [3]. For example, expres-
sion of miR-155 in BC (normalized median = 1.75, range
0.95-11.45) and in control tissue (1.37, 1.11-1.88) was
found significantly different according to ANOVA [3].
Moreover, additional oncomiRs such as miR-17-92 cluster
is also deregulated in BC and contributes to transformed
BC characteristics [4] possibly through significant changes
in target gene expression [5]. Several oncomiRs are poten-
tially involved in aggressiveness including let-7b, miR-30c,
miR-148a, miR-181a, miR-181a*, and miR-181b based on
next generation sequencing study of several cases of highly
invasive micropapillary carcinoma [6].
Notably, several miRs including miR-24 and miR-181b
displayed co-upregulation in sera and tumor tissue of
BC patients (N = 13) compared to controls (N = 10)
using sequencing approach [7]. While several miRs are
repeatedly deregulated others are stable and show very
little variability in sera such as: let-7a, miR-16, miR-93,
miR-103, miR-192, and miR-451 in a study of gastric
cancer patients [8] or: let-7a and miR-195 in BC patient
plasma as compared to normal controls [9]. Let-7a levels
are stable likely because it is widely expressed in som-
atic cells, while less expressed in rare stem cells and
undifferentiated precursors [10]. In agreement, let-7a
was found slightly downregulated in several malignan-
cies including breast cancer samples [11] and upon BC
tumorigenesis [12,13].
Based on above-mentioned data the miR-155, miR-19a,
miR-181b, and miR-24 represent very good candidates
to monitor tumor growth in BC patients as serum mo-
lecular biomarkers (albeit there are possibly other
oncomiRs involved in BC pathogenesis, aggressiveness,
or tumor growth). A direct role of these oncomiRs in
BC pathogenesis is supported by studies on their target
genes respectively. For example, the oncomiR miR-155 is
overexpressed in BC and functions to downregulate
Suppressor of cytokine signaling-1 (SOCS1) leading to
persistent activation of the Signal Transducer and
Activator of Transcription-3 (STAT3) [14]. Indeed, up-
regulation of miR-155 upon diagnosis of BC and a de-
crease of its levels upon therapy was previously observed
based on data using the spike-in control [15]. Interest-
ingly, the decline of serum miR-155 levels following
therapy was observed much earlier than that of other
tumor-biomarkers [15]. Next, miR-19a, a member of the
miR-17-92 cluster, affects BC pathogenesis by multiple
mechanisms including inhibition of tumor suppressorPTEN [16]. Involvement of miR-181b is suggested in ag-
gressive BC due to its role in DNA damage response by
downregulating ATM and signal efficiency of PARP1 in-
hibitors in the treatment of triple-negative BC [17].
Recently, expression of miR-19a and miR-181b has been
interlinked by a study showing that miR-19a-mediated in-
hibition of SOCS1 activates miR-181b expression (through
STAT3) [18]. In BC pathogenesis, role of TGFβ-mediated
epithelial-to-mesenchymal transition has been repeatedly
suggested with a focus on miR-24 role in this process
[19]. Taken together, microRNAs selected for this study
are key molecules involved in tumor growth and aggres-
siveness of BC.
We herein studied expression of miR-155, miR-19a,
miR-181b, and miR-24 in sera of 63 EBC patients and
evaluated statistically significance of their expression
throughout the therapy and in relation to clinical risk
stratification. Our work suggests that the serum-oncomiR
expression associates with EBC at diagnosis especially in
high-risk patients and can be potentially useful for disease
monitoring.
Patients, materials, and methods
Patient inclusion and sample collection
Patient sera, collected in years 2010–2013 from EBC
(N = 63, median age 58) was obtained following written
informed consent based on Helsinki declaration and ap-
proved by Ethics Committee of the Regional Hospital in
Liberec, Czech Republic (under #EK/83/2010). Written
informed consent for publication of patients clinical de-
tails was obtained. EBC is defined as a BC that has not
spread beyond the breast or the axillary lymph nodes
(this includes ductal carcinoma in situ and invasive BC
stages I, IIA, IIB and IIIA). Timing of sera collection in
each patient was: one day prior operation (time point I),
14–28 days after operation before any non-surgical treat-
ment (time point II) and 14–28 days after first treatment
modality: either chemotherapy or radiotherapy (time
point III). The surgery involved in all patients the tumor
removal together with the successful removal of sur-
rounding non-tumorous tissue. Median follow-up was
27 months (ranges 9.5-36.3) (see Additional file 1). Upon
clinical relapse the patients (N = 3) donated another
serum sample (time point IV). Diagnosis and therapy de-
cisions were made using standard criteria and were not
influenced by any results presented in this manuscript.
Blood samples were collected into 10 cc tubes with poly-
mer gel and clot activator (BD Vacutainer SST™ Tubes),
allowed to clot in room temperature for 30–60 minutes,
spun at 3000 rpm for 10 minutes, and aliquoted and
placed into −80°C freezer.
Clinical parameters of EBC patients include age, meno-
pausal status, personal cancer history, histological diag-
nosis, clinical and surgical stage, tumor type, tumor
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pression (see Additional file 1). High-risk group patients
presented with one or more of the following characteris-
tics: triple-negativity (ER, PgR and HER2 negative), HER2
positivity, grade III, Ki-67 ≥ 20%, and axillary lymph-
node positivity. Low-risk patients were negative for
these characteristics. Normal serum samples were ran-
domly collected from 21 healthy female-volunteers (age
ranges 25–60 years) during the same time period. Con-
trol sera were obtained following written informed con-
sent based on Helsinki declaration and approved by
Ethics Committee of the Regional Hospital in Liberec,
Czech Republic (under #EK/83/2010). Written informed
consent for publication of healthy controls clinical details
was also obtained.
Sample processing and miRNA extraction and quantitation
RNA was isolated using miRNeasy® Mini Kit (Qiagen)
from 200 μL of sera (lysed by 1 ml of QIAzol® Lysis
reagent) with several modifications including a) vigor-
ous vortexing after mixing with CHCl3, b) centrifuga-
tions at 10800 rpm/15 min/at 4°C, c) use of glycogen
during ethanol precipitation, d) multiple (3×) washes
with 500 μl RPE buffer, and e) elution volume to be
40 μl of DNAse&RNAse-free water. RNA level was too
low to be detectable by NanoDrop. Reverse transcrip-
tion was performed using High Capacity cDNA Reverse
Transcription Kit supplemented with miR-specific primers
(Life Technologies, USA). Quantitative polymerase chain
reaction (PCR, using the ABI 7900HT instrument) was
run 40 cycles of 95°C for 15 seconds and 60°C for
1 minute. Relative expression was calculated from CTs
of the oncomiR (miR-155, miR-19a, miR-181b, miR-24)
relative to let-7a in EBC vs healthy sera using 2-(ΔCT)
equation. Mean values and the standard deviation of
the dCT values (of each sample and average control
sample) of reference microRNA let-7a in the patient
samples at each collection time (I-III) and in the con-
trol samples document that let-7a is stably expressed in
the serum samples (meanI = −0.06818 stdevaI = 0.6640;
meanII = −0.01103 stdevaII = 0.8948; meanIII = 0.01014
stdevaIII = 0.8488; meanCTRL = 0.05397 stdevaCTRL = 0.6604).
Statistical analysis of the serum levels of oncogenic miRs
in BC patients over therapy
Serum levels of the oncogenic miRs (miR-155, miR-19a,
miR-181b, and miR-24, all relative to let-7a) are re-
corded for each BC patient at three time points over the
therapy: diagnosis (I), after surgical resection (II), and
after chemo- and/or radio-therapy (III). Serum levels in
case of female controls are measured only once, i.e., at
time point I (control diagnosis).
Longitudinal multivariate data analysis is performed
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Here, E[miRi,t|bi] is the conditional expectation of the
miR’s serum level miRi,t for each
BC patient/control identification i at time point t = I,
II, III given random intercept bi, which is specific for
each BC patient/control and has a multivariate normal
distribution with zero mean. The unconditional distribu-
tion of the miR’s serum level is a Gamma distribution.
Themathematical syntax of expression, e.g., (Patienti in II),
is that it equals one if and only if the ith BC patient/control
is in time point II (and, hence, is not a control); zero
otherwise.
Results
Longitudinal multivariate data analysis model to evaluate
oncomiR levels in EBC
We determined the levels of oncomiRs in sera relative
to let-7a and obtained a set of values from one day
prior operation (time point I), 14–28 days after oper-
ation before any non-surgical treatment (time point II)
and 14–28 days after first treatment modality: either
chemotherapy or radiotherapy (time point III). These
values (as shown in Additional file 2: Results 1) show
that a large portion of the patients at time points I & II
displayed differences when compared to healthy control
and time point III samples. In order to statistically
evaluate the data, we constructed and used Longitu-
dinal multivariate data analysis model (see Methods)
for each of the oncomiR. This enabled the analysis of
each oncomiR levels within EBC patient sera with respect
to time points and risk factors. Additionally, we aimed to
define the expected level of each oncomiR at each time
point.
The parameters of the longitudinal data model (i.e.,
estimates of parameters βs) are shown in Table 1A-D
(miR-155 in A, miR-19a in B, miR-181b in C, and miR-24
in D). βI represents oncomiR level at time point I, βII
compares oncomiR levels between time points I and II,
βIII reflects the difference between time points I and III
βC, stands for the difference between time point I and
healthy control. Finally, βL represents the difference
Table 1 Summary of the multivariate longitudinal data
analysis
A) miR-155
Parameter Estimate Standard error p-value
βI 0.61774 0.06440 < 2e-16
βII −0.24024 0.05617 1.89e-05
βIII −0.34474 0.05684 1.32e-09
βC −0.51148 0.11103 4.10e-06
βL −0.18353 0.08245 0.026
B) miR-19a
Parameter Estimate Standard error p-value
βI 0.60941 0.04843 < 2e-16
βII 0.03224 0.03187 0.31183
βIII 0.09981 0.03804 0.00869
βC 0.34506 0.11439 0.00256
βL 0.15711 0.07041 0.02567
C) miR-181b
Parameter Estimate Standard error p-value
βI 0.70370 0.05176 < 2e-16
βII 0.17814 0.03917 5.41e-06
βIII 0.17263 0.03884 8.80e-06
βC 0.27792 0.10095 0.0059
βL 0.16588 0.07403 0.0250
D) miR-24
Parameter Estimate Standard error p-value
βI 0.50276 0.06718 7.19e-14
βII −0.14807 0.05429 0.00638
βIII −0.12527 0.05527 0.02343
βC −0.34034 0.11512 0.00311
βL −0.22631 0.08774 0.00990
Presented are parameters to calculate conditional expectation of the miR’s serum
level for each BC patient/control at particular time point and their estimate values,
their standard errors, and corresponding p-values for levels of miR-155 (A), miR-19a
(B), miR-181b (C), and miR-24 (D), all relative to let-7a, in EBC sera. Parameters of
oncomiR level: βI: time point I, βII: the difference between time points I and II, βIII:
the difference between time points I and III, βC: the difference between time point
I and healthy control, and βL: the difference between high risk and low risk
EBC patients.
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Estimated parameter values are used to calculate condi-
tional expectation of the miR’s serum level for each BC
patient/control at particular time point (see equations
in Methods).
To exemplify this model; the prediction of miR-19a
after therapy for a high-risk BC patient, the predicted
serum level of that miR is 1/{0.60941 + 0.09981} ≈ 1.410
(see parameter estimates from Table 1B). On the other
hand, the predicted serum level of miR-24 for a low-risk
BC patient after surgical resection is exp{0.50276 +
(−0.14807) + (−0.22631)} ≈ 1.137 (see Table 1D).Levels of oncomiRs decrease after surgery and adjuvant
therapy of EBC patients
Using the longitudinal multivariate data analysis we
asked whether levels of oncomiRs are different at EBC
time point I compared to other time points or controls.
Firstly, we determined whether surgical removal of a
tumor had any impact on serum oncomiR levels. Be-
tween time points I and II the serum levels of miR-155,
miR-181b, and miR-24 significantly decreased after the
surgical resection (p-values < 0.05, i.e., 1.89e-05, 5.41e-
06, and 0.00638, respectively) for all (low- and high-risk)
EBC patients. p-values are shown in the Table 1A-D.
Unlike these three oncomiRs (miR-155, miR-181b, and
miR-24), serum levels of miR-19a did not change after
surgery indicating that either it is more stable or its pro-
duction does not reflect loss of tumor tissue. However, a
significant drop of serum level of each miR (including
miR-19a) was noted after the therapy at time point III
compared to the time point I at diagnosis (p-values < 0.05,
i.e., miR-155: 1.32e-09, miR-19a: 0.00869, miR1-81b: 8.80e-
06, and miR-24: 0.02343, respectively). It is thus more likely
that the absence of any change in miR-19a serum levels
upon surgery is due to a stability issue rather than miR-19a
production by the non-tumor tissue. Data are comprehen-
sively presented by the Figure 1 and the Table 1.
In summary, the oncomiR levels are significantly dif-
ferent between diagnosis and following the surgical tumor
removal (between time points I and II) except miR-19a that
appears to be more stable at time point II and decreases
following the adjuvant therapy (time point III). Further-
more, the oncomiR’s serum level for healthy female is sig-
nificantly lower than the oncomiR’s serum level at time
point III of EBC patients.
High-risk EBC patients express increased oncomiRs
compared to low-risk EBC patients
We asked whether high-risk patients have different onco-
miR serum levels compared to low-risk EBC patients, we
first dichotomized EBC patients according to risk param-
eters (see Methods). Indeed, high-risk EBC patients
possessed higher serum levels of oncomiRs’ (miR-155,
miR-19a, miR-181b, and miR-24) than female-healthy con-
trols (p-values 4.10e-06, 0.00256, 0.0059, and 0.00311)
while the low-risk patients tend to have smaller oncomiRs’
values than the high-risk ones (p-values 0.026, 0.02567,
0.0250, and 0.00990). Therefore, it is strongly suggested
that there might exist oncomiR level that distinguishes
EBC patients according to risk for diagnostic purpose. Not-
ably, the clinical data involving risk stratifications are in
significant agreement with levels of all four oncomiRs (see
Table 1A-D and Figure 1).
The next question was how the levels of oncomiRs
respond to therapy according to risk stratification. The
serum level for each miR in case of high-risk patients
Figure 1 Conditional expectation of the serum level of miR-155, miR-19a, miR-181b, and miR-24 through the therapy in case of a
common BC patient (high-risk patients in upper A panel, low-risk patients in bottom B panel) and its comparison to the control. The
predicted development (mainly decrease) of the serum level for each oncomiR is calculated using the multivariate longitudinal data analysis
introduced within Methods and Results sections and also provided in the Table 1.
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through the therapy. The only exception is serum levels
of miR-24, which was consistently low before and after
therapy (between time points II and III). On the other
hand, the oncomiRs of low-risk patients (Figure 1,
bottom B panel) drop after the surgical resection and,
consequently, remain almost constant during the therapy
with approximately the same level as in case of controls.
To conclude, the levels of oncomiRs of high-risk patients
drop less rapidly than low-risk patients. In addition, the
high-risk patients do not achieve normal oncomiR levels as
the low-risk patients do.
Discussion
We herein present evidence that oncomiR levels are sig-
nificantly different at initial diagnosis of EBC compared
to time points following specific treatments (after sur-
gery and after adjuvant therapy). Our results suggest that
surgery had tremendous impact on three serum onco-
miR levels while adjuvant therapy significantly decreased
all of the four oncomiRs studied. This suggests that there
exist relationship between EBC elimination throughout the
therapy and serum oncomiR levels.
OncomiRs are often deregulated in solid cancers and
leukemias and function in the gene-reprogramming of
the cell to establish the phenotypic outcome. As such,
their levels are accordingly detectable in patient sera at
diagnosis and are thus strongly considered for diagnostic
screening in cancer patients and their relatives [2]. Ourother data confirm that BC tumor tissues indeed produced
the studied oncomiRs and that their elevated levels in the
sera reflect this (Additional file 2: Results 2). In addition,
detection of oncomiRs can be useful for relapse detection
however much longer follow up is needed. In our patient
cohort, we observed BC relapse in three patients and this
resulted in changes in oncomiR levels (Additional file 2:
Results 3). However, as our cohort consisted of a low num-
ber of relapsed patients it did not allow more thorough
analysis of oncomiRs. MiR-155 is one of the most studied
miRs in BC patients and its levels were found consistently
increased by others in the serum samples [15]. However,
miR-155 production by a tumor is highly responsive to
surgical therapy and therefore its levels decline very rap-
idly (similarly to our data). Contrary to this, miR-19a ap-
pears to be more stable and detectable following the
surgical removal (as compared to miR-155, miR-181b, or
miR-24). Finally, the levels of all studied oncomiRs de-
creased following the adjuvant therapy (time point III).
Our study demonstrated that the levels of oncomiRs
for the high-risk patients’ drop less rapidly than in case
of the low-risk patients. In addition, high-risk patients,
unlike low-risk, do not achieve normal oncomiR levels
following the adjuvant therapy (time point III). For ex-
ample, miR-17-92 cluster appears to be very important
factor in aggressive triple-negative BC [16]. Similarly,
additional microRNA miR-181b was associated with
more aggressive BC characterized by grading, Ki-67, and
triple negativity (its pathogenic effect was linked to
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response [17]). miR-24 has been associated with BC patho-
genesis [19], but has not been so far suggested to be in-
volved in BC aggressiveness. We also consider and cannot
fully exclude the possibility that oncomiR levels drop less
rapidly in high-risk patients due to post-surgical pres-
ence of tumor cells that are not however detectable by
clinically-utilized techniques. However, both careful surgi-
cal removal of surrounding non-tumorous tissue as well as
very low number of relapsed EBC patients suggests that
the elevation reflects rather increased stability and possibly
also slower turnover of the oncomiRs in the patient sera.
Longitudinal multivariate analysis of oncomiR expression
in the EBC patient cohort strongly supports the clinical
relevance of the four oncogenic microRNAs. In part it
helps to associate observed deregulations in the serum
samples with aggressive clinical parameters such as HER2,
Ki-67, and grade III. This is consistent with previous ana-
lyses that were based on expression-data within tumor tis-
sue [17] and some of the data with regard to miR-155 in
sera were also consistent with others [20]. Our work thus
provides important link in connecting biological function
of miRs within the tumor with their levels in the sera.
Conclusions
Our data provide evidence that the expression of four
BC pathogenesis-related oncomiRs (miR-155, miR-19a,
miR-181b, and miR-24) in sera are increased at diagnosis
of EBC patients. These oncomiR levels decrease following
combined therapy. Importantly, high-risk EBC patients
show notably delayed and less-pronounced decrease of
oncomiR expression following surgical tumor removal. Ele-
vated expression of the oncomiRs in sera was also observed
in primary tumor tissues. Upon relapse, serum levels of
some oncomiRs are increased indicating their potential for
the EBC patient monitoring. Multivariate analysis of the
oncomiR expression in the EBC patient cohort suggested
that adverse clinical characteristics associate with elevated
oncomiRs in the EBC sera. OncomiR-profiling in sera is
very promising tool to be incorporated in further studies
and clinical practice as well.
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